Shire Acquires Fibrotech

Article

Shire acquires Fibrotech for $75 million.

Shire will take over the development of Fibrotech’s product FT011, which has completed a Phase 1A study in healthy volunteers and is currently in a Phase 1B study in patients with diabetic nephropathy. Subject to successful completion of this trial, the first Phase 2 study is expected to be initiated to enroll focal segmental glomerulosclerosis (FSGS) patients next year. In addition to FT011, Shire has acquired Fibrotech’s library of molecules including FT061, in pre-clinical development that is similar to FT011. It is an oral small molecule that could address both the inflammatory and pro-fibrotic components of fibrosis.

The closing of the acquisition is subject to customary conditions, including approval of Australia's Foreign Investment Review Board.

Source: Shire

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content